358 related articles for article (PubMed ID: 33294467)
1. Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors.
Joshi M; Ansell SM
J Immunol Res; 2020; 2020():8820377. PubMed ID: 33294467
[TBL] [Abstract][Full Text] [Related]
2. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of immune checkpoint inhibition in malignant lymphoma.
Hude I; Sasse S; Engert A; Bröckelmann PJ
Haematologica; 2017 Jan; 102(1):30-42. PubMed ID: 27884973
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
5. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver KA; Croom-Perez TJ; Copik AJ
Front Immunol; 2021; 12():679117. PubMed ID: 33995422
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
Xia Y; Medeiros LJ; Young KH
Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
[TBL] [Abstract][Full Text] [Related]
7. Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go.
Barroso-Sousa R; Tolaney SM
Curr Treat Options Oncol; 2020 Jun; 21(7):59. PubMed ID: 32556894
[TBL] [Abstract][Full Text] [Related]
8. Immune and Cell Therapy in Non-Hodgkin Lymphoma.
Merryman RW; Houot R; Armand P; Jacobson C
Cancer J; 2020; 26(3):269-277. PubMed ID: 32496460
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies.
Tun AM; Ansell SM
Cancer Treat Rev; 2020 Aug; 88():102042. PubMed ID: 32521386
[TBL] [Abstract][Full Text] [Related]
10. The evolving role of lenalidomide in non-Hodgkin lymphoma.
Galanina N; Petrich A; Nabhan C
Leuk Lymphoma; 2016 Jul; 57(7):1507-16. PubMed ID: 26902680
[TBL] [Abstract][Full Text] [Related]
11. The role of immune checkpoint inhibitors in anaplastic thyroid cancer (Case Series).
Sukari A; Kukreja G; Nagasaka M; Shukairy MK; Yoo G; Lin HS; Hotaling J; Kim H
Oral Oncol; 2020 Oct; 109():104744. PubMed ID: 32402656
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulators in Lymphoma.
Anagnostou T; Ansell SM
Curr Treat Options Oncol; 2020 Mar; 21(4):28. PubMed ID: 32193838
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint inhibition in lymphoma.
Shah GL; Moskowitz CH
Clin Adv Hematol Oncol; 2018 Jan; 16(1):45-55. PubMed ID: 29741505
[TBL] [Abstract][Full Text] [Related]
15. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
Zhang N; Wei L; Ye M; Kang C; You H
Front Immunol; 2020; 11():592612. PubMed ID: 33329578
[TBL] [Abstract][Full Text] [Related]
16. Targeting indolent non-Hodgkin lymphoma.
Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors.
Xiao Y; Zeng L; Shen Q; Zhou Z; Mao Z; Wang Q; Zhang X; Li Y; Yao W
J Immunol Res; 2020; 2020():2640273. PubMed ID: 32832568
[TBL] [Abstract][Full Text] [Related]
18. Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer.
Jin KT; Wang SB; Ying XJ; Lan HR; Lv JQ; Zhang LH; Motallebnezhad M; Mou XZ
Immunol Lett; 2020 May; 221():61-71. PubMed ID: 32097671
[TBL] [Abstract][Full Text] [Related]
19. Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer.
Dermime S; Merhi M; Merghoub T
Front Immunol; 2021; 12():781872. PubMed ID: 34745152
[No Abstract] [Full Text] [Related]
20. Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma.
Zeng FL; Chen JF
Technol Cancer Res Treat; 2021; 20():15330338211039952. PubMed ID: 34528830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
